Procyon is a new cancer diagnostics spinout from Queen Mary University of London which exemplifies the type of investable, impact-driven spinout we’re creating at Queen Mary. The company combines world-class academic research with commercial leadership and investor backing from the start. Their activity will bring immense benefits to patients and their families.

Procyon’s first product, planned for early 2026, will be the PancRISK test, invented by Queen Mary’s Professor Tatjana Crnogorac-Jurcevic, to detect pancreatic cancer. 

The underlying science was published in Clinical Cancer Research, and the test is currently being validated through a multi-centre clinical trial, UroPanc. Procyon’s exclusive worldwide license covers the patented test, machine learning algorithm and trademark. The company has formed a strategic partnership with Personalised Diagnostics Limited for the user interface, secure digital storage and algorithmic analysis. Source Bioscience will provide testing services and help in managing partner laboratories to scale up testing.

PancRISK will be the first of many single-cancer early detection tests commercialised by Procyon. The company aims to be a lead provider of biomarker technologies for detecting early-stage cancers, with target markets including Europe, North America, and the Middle East. Alongside testing, Procyon will use the data collected for further research to develop more new non-invasive tests, primarily based on body fluids such as blood and urine.

Investor interest in Procyon exceeded our target, underlining the demand for practical, high-accuracy cancer detection.